GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Exelixis Inc.
Exelixis is a biotech company focused on cancer treatment. Its stock price is heavily dependent on sales of its key drug, Cabometyx, and its success in expanding its use. The chart shows how a single successful blockbuster can determine the company's fate.
Share prices of companies in the market segment - Oncology targeted therapy
Exelixis is a biotech company focused on cancer treatment. We classify it as a targeted oncotherapy company. The chart below illustrates the overall dynamics of this sector, where the success of a single drug can determine the value of the entire company.
Broad Market Index - GURU.Markets
Exelixis is an oncology company focused on the discovery, development, and commercialization of drugs for the treatment of difficult-to-treat cancers. Its market capitalization earns it a spot in the GURU.Markets index. The chart below shows the overall market performance. Compare this biotech player's stock to the overall trend.
Change in the price of a company, segment, and market as a whole per day
EXEL - Daily change in the company's share price Exelixis Inc.
For Exelixis, an oncology company, daily price changes are a measure of its volatility and response to clinical trial data. The graph of these fluctuations is unspectacular, but they are an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Exelixis, Inc. is a biotech company focused on oncology. This chart highlights the sector's high volatility. Comparing it to EXEL, whose success is heavily dependent on its cancer drugs, helps assess its risks compared to more diversified pharma giants.
Daily change in the price of a broad market stock, index - GURU.Markets
Exelixis is a biopharmaceutical company specializing in the development of cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating Exelixis shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Exelixis Inc.
Exelixis is a biotech company with a successful oncology pipeline. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough products.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Exelixis, Inc. is a biotechnology company focused on developing and commercializing drugs to treat cancer. Its success depends largely on its key drug. This chart shows how its scientific advancements and efforts to expand the reach of its drugs influence its performance in the oncology sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exelixis is a biotech company specializing in cancer treatment. Its growth is driven by sales of its key drugs and clinical trial successes. It's a science-driven growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Exelixis Inc.
The value of Exelixis, a biotech focused on oncology, depends on the success of its drugs. The monthly fluctuations on the chart reflect sales data for its flagship drug, Cabometyx, as well as news about clinical trials that could expand its use and shape the company's future.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
This chart reflects the dynamics of the biotech sector. For Exelixis, an oncology company, it's the backdrop. Its movements demonstrate how the commercial success of its lead drug and progress in clinical trials allow it to compete successfully in this volatile industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exelixis is a biotech company whose fate depends less on overall market sentiment than on its own scientific achievements. Its shares are preoccupied with anticipation of clinical trial data. The chart below shows the market's pulse, but for Exelixis, a single successful drug can drive growth even during a general downturn, and vice versa.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Exelixis Inc.
Exelixis is a biotech company focused on oncology. Its shares fluctuate from news to news. Clinical trial data, FDA decisions, and competitor successes cause sharp weekly fluctuations, demonstrating the high risk and potential for profitability in the sector.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Exelixis is a biotech company where the success of a single drug determines the fate of its entire stock. Comparing its weekly performance to the biotech sector can be misleading. The chart shows how news about clinical trials or sales of its key drugs can give the stock a life of its own, independent of overall industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Exelixis, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
EXEL - Market capitalization of the company Exelixis Inc.
Exelixis's market capitalization is a visual saga of cancer drug development and commercialization. The company's chart focuses on the success of its oncology drugs. Its dynamics are a roller coaster, reflecting clinical trial results, regulatory decisions, and competition in the targeted therapy market.
EXEL - Share of the company's market capitalization Exelixis Inc. within the market segment - Oncology targeted therapy
Exelixis is a biotechnology company focused on the development and commercialization of cancer treatments. Its market share in the oncology sector reflects the success of its key drugs and expectations for future developments. The chart below shows Exelixis's market share in the highly competitive cancer therapy market.
Market capitalization of the market segment - Oncology targeted therapy
Exelixis is a biotech company focused on developing cancer drugs. It is part of one of the most innovative and valuable sectors of medicine. The chart below shows the overall market capitalization of the oncology segment. Its dynamics reflect both scientific breakthroughs and the massive investments in the fight against cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Exelixis chart shows a company at the forefront of the fight against cancer. Its market capitalization is directly dependent on the success of clinical trials and the approval of new drugs. This is a visualization of a risky but vital biotech business, where every success can change both lives and the market.
Book value capitalization of the company, segment and market as a whole
EXEL - Book value capitalization of the company Exelixis Inc.
For Exelixis, book value reflects capital invested in years of scientific research, patents for anti-cancer drugs, and financial reserves for future development. This is the biotech company's scientific and financial foundation. The chart shows how successful clinical trials and drug commercialization have impacted the growth of its capital base.
EXEL - Share of the company's book capitalization Exelixis Inc. within the market segment - Oncology targeted therapy
Exelixis fights cancer at the molecular level, not on a factory assembly line. The company's primary assets are research and development laboratories. The chart shows a modest share of physical assets, as its primary value lies in drug patents and scientific discoveries, not large-scale production equipment.
Market segment balance sheet capitalization - Oncology targeted therapy
Exelixis's biotech business requires significant investment in R&D, but not in giant factories during the development phase. The company is capital-intensive from a scientific perspective. The BCap_Seg chart for the biotech sector shows that the industry as a whole relies on laboratories rather than large-scale production facilities.
Book value of all companies included in the broad market index - GURU.Markets
The assets of Exelixis, a biotech company, are not factories, but cutting-edge research laboratories and an accumulated portfolio of cancer drug patents. Its book value reflects the capital invested in science and intellectual property. The chart below illustrates the scale of these intangible yet valuable assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Exelixis Inc.
Exelixis's balance sheet consists of its laboratories and capital. The enormous premium the market pays reflects the valuation of its successful oncology drugs, primarily cabozantinib, and the potential of its R&D platform to create new drugs. The schedule is a bet on the future success of its science.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Exelixis is a biotech company whose value is almost entirely dependent on its portfolio of cancer drugs and research. Despite its modest tangible assets, its market valuation is enormous. The chart reflects the premium investors pay for the potential of its intellectual property.
Market to book capitalization ratio for the market as a whole
Exelixis is a biotech company focused on cancer treatment. Its core assets are the patents on its existing drugs and the potential for future discoveries. These intangible assets drive its market valuation, which is a multiple of its book value. This chart shows how investors evaluate the company's scientific potential.
Debts of the company, segment and market as a whole
EXEL - Company debts Exelixis Inc.
Exelixis, a biotech focused on oncology, uses its financial position and debt to fund clinical trials of new drugs. R&D in this field is extremely expensive, and debt capital can accelerate drug delivery to market. This chart illustrates how the company is investing in its scientific potential to fight cancer.
Market segment debts - Oncology targeted therapy
Exelixis is a biotech company focused on oncology. Drug development requires significant and risky investments. Its debt policy reflects confidence in the success of clinical trials. Many companies in the sector avoid debt until product commercialization. This chart shows the financing strategy Exelixis has chosen for its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Exelixis Inc.
Exelixis is a biotech company focused on oncology, where research and clinical trial costs are enormous. This chart shows how the company finances its expensive research activities. Low debt may indicate financial independence based on revenues from approved drugs.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Exelixis is a biotech company focused on developing cancer drugs. Research and clinical trials require significant capital, often borrowed. This chart shows how the debt burden incurred for R&D relates to the overall capitalization and financial risks of the entire innovative oncology sector.
Debt to book value of all companies in the market
Exelixis, a biotech company, is investing heavily in R&D to develop cancer drugs. This chart allows us to assess the scale of these risky investments by comparing the company's debt to the total capitalization of the entire stock market. This places the risks of biotech in a broader economic context.
P/E of the company, segment and market as a whole
P/E - Exelixis Inc.
Exelixis is a biotech company focused on developing and commercializing cancer drugs. This chart shows the stock price-to-earnings ratio. Its performance is heavily dependent on the success of key drugs, clinical trial results, and the potential of new developments, reflecting both current sales and hopes for future blockbusters.
P/E of the market segment - Oncology targeted therapy
Exelixis is a biotech company whose future depends on the success of its oncology drugs. This chart displays the average earnings estimate for the biotech sector. It provides insight into how investors value Exelixis: whether the market is rewarding its successful commercial products or whether its valuation reflects the industry-wide risks of clinical trials.
P/E of the market as a whole
Exelixis is a biotech company focused on developing cancer drugs. Its value is directly dependent on the success of clinical trials and drug sales. This chart shows the company's overall risk appetite. It's important for Exelixis because during periods of optimism, the market is willing to finance expensive and risky developments, while during periods of fear, it demands proven profitability.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Exelixis Inc.
Exelixis is a biotech company focused on developing drugs for the treatment of oncology. This chart illustrates market expectations for sales of its key drugs and the success of clinical trials of new candidates. The dynamics of this indicator reflect investors' confidence in the future drug pipeline.
%20P%2FE%20Exelixis%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Exelixis-Inc.&v=1772513604885 "Chart of the company's future (projected) P/E Exelixis Inc.")
Future (projected) P/E of the market segment - Oncology targeted therapy
Exelixis is a biotechnology company focused on developing and commercializing cancer drugs. This chart shows average profitability expectations in the targeted oncology sector. It allows investors to assess how the potential of the company's current drugs and R&D pipeline compares to that of its competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772513604889 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Exelixis is a biotech company focused on developing and commercializing drugs for the treatment of oncology. This chart reflects general expectations for stock market returns. For a company whose success depends on clinical trial results and patents, it provides a backdrop, highlighting investor appetite for risk in the innovative sector.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513604908 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Exelixis Inc.
Exelixis is a biotechnology company focused on developing drugs for the treatment of oncology. The bottom line, illustrated by this chart, is primarily generated by sales of its key drugs. The trend reflects the commercial success of these drugs and the investment in clinical research to expand their use.
Profit of companies in the market segment - Oncology targeted therapy
Exelixis is a biotechnology company focused on developing and commercializing drugs to treat oncology. Its financial success depends on sales of its flagship drugs and clinical trial results. This chart shows the overall profitability of the targeted therapy sector, where Exelixis's breakthroughs in cancer treatment save lives and generate revenue.
Overall market profit
Exelixis is a biotechnology company specializing in cancer drug development. Its success depends on the results of clinical trials and drug commercialization. Although demand for oncology drugs is inelastic, the healthcare system's ability to pay for expensive innovations is tied to the overall health of the economy, which is indirectly reflected in this graph.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Exelixis Inc.
Exelixis is a biotechnology company focused on the development and commercialization of oncology drugs. The profit forecast in this chart depends on sales volumes of its key drugs and the clinical trial success of new candidates. Analysts assess the market potential of the drug portfolio and the competitive environment.
%20profit%20of%20the%20company%20Exelixis%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Exelixis-Inc.&v=1772513604964 "Graph of future (projected) profit of the company Exelixis Inc.")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Exelixis is a biopharmaceutical company focused on the development and commercialization of cancer treatments. Its lead product, cabozantinib, is the core of its business. This chart shows the revenue forecast for the oncology therapeutics segment, allowing one to assess the market potential of Exelixis and its drug portfolio within the context of the overall industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772513604965 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Exelixis is a biotech company focused on developing cancer treatments. Demand for its drugs is less dependent on short-term economic cycles, but the overall economic situation, reflected in the chart, impacts healthcare funding and patients' ability to afford expensive treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513604966 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Exelixis Inc.
Exelixis is a biotech company focused on developing cancer drugs. This chart shows how the market views its revenue, which is largely dependent on the success of several key drugs. The dynamics of this indicator reflect investor expectations for sales growth and clinical trial results.
P/S market segment - Oncology targeted therapy
Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative drugs for the treatment of oncology. Its key drug, Cabometyx, generates the majority of its revenue. This chart compares how investors view Exelixis's scientific potential and commercial success relative to other companies in the sector.
P/S of the market as a whole
Exelixis is a biopharmaceutical company focused on the development and commercialization of cancer treatments, specifically cabozantinib. In biotech, revenue depends on the success of clinical trials and patents. This chart helps understand how the market assesses the risks and potential of the biotech sector against the backdrop of the overall economic situation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Exelixis Inc.
Exelixis is a biotechnology company specializing in cancer drug development. This chart shows how the market values the company based on its future sales. It reflects investor expectations regarding the success of its current oncology drugs and the potential of future developments in clinical trials.
%20P%2FS%20Exelixis%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Exelixis-Inc.&v=1772513605029 "The graph of the company's future (projected) P/S Exelixis Inc.")
Future (projected) P/S of the market segment - Oncology targeted therapy
Exelixis is a biotechnology company focused on the discovery and development of innovative cancer treatments. Its key drugs target difficult-to-treat forms of cancer. This metric reflects how investors view its future sales potential relative to other companies in the oncology therapeutics sector.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772513605040 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Exelixis is a biotechnology company focused on developing cancer drugs. Its future revenue depends on the success of clinical trials and drug commercialization. This general expectations chart for Exelixis is not a direct driver. The company's success is determined by scientific breakthroughs, not the overall economic climate, which creates its own trend.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513605048 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Exelixis Inc.
This chart depicts a success story in the biopharmaceutical industry. Exelixis's financial performance is driven almost entirely by global demand for its flagship drug, CABOMETYX®, which is used to treat several types of cancer. The chart's dynamics are directly related to the drug's effectiveness and acceptance.
Sales of companies in the market segment - Oncology targeted therapy
Exelixis is a biotechnology company focused on the development and commercialization of cancer treatments. Its sales, primarily from its flagship drug CABOMETYX, account for a significant portion of the targeted therapy market. This chart shows how clinical trial successes and expanded indications impact revenue for Exelixis and the broader oncology sector.
Overall market sales
Exelixis is a biotechnology company focused on developing drugs for the treatment of cancer. Its commercial success depends on demand for innovative therapies. Although this is a highly specialized market, it is part of the vast healthcare industry, whose spending accounts for a significant share of GDP and contributes to the overall economic picture.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Exelixis Inc.
Exelixis is a biotechnology company focused on the development and commercialization of drugs for the treatment of oncology. Future sales forecasts depend on the success of its key drugs and the results of clinical trials of new candidates. This chart demonstrates analysts' confidence in the company's scientific and commercial potential.
%20sales%20of%20the%20company%20Exelixis%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Exelixis-Inc.&v=1772513605071 "Schedule of future (projected) sales of the company Exelixis Inc.")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Exelixis is a biotech company focused on cancer drug development. The forecast for the oncology targeted therapy segment reflects the pace of innovation and demand for new treatments. This chart helps understand how the company's scientific breakthroughs fit into the overall development of the oncology market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772513605075 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Exelixis is a biotechnology company specializing in cancer drug development. Demand for its oncology drugs is not dependent on short-term economic cycles. However, the overall economic situation, reflected in this chart, can impact public and private healthcare systems and their ability to finance expensive treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513605096 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Exelixis Inc.
For Exelixis, a biotech company focused on oncology, this chart reflects the commercial success of its drugs. High profitability is driven by sales of key, patent-protected cancer drugs. The trend shows how revenue from these blockbusters covers the enormous costs of research and development for new drugs.
Market segment marginality - Oncology targeted therapy
Exelixis is a biotechnology company focused on developing and commercializing drugs for the treatment of oncology. This chart shows the average profitability in the biotechnology sector. The success of key drugs such as cabozantinib and effective research management enable the company to generate profitability significantly above the industry average.
Market marginality as a whole
Exelixis, Inc. is a biotechnology company focused on developing and commercializing drugs to treat cancer. This chart shows the company's overall profit margin. It illustrates how the success of one or more drugs can generate high profit margins, which are then reinvested in an extensive clinical development program for future growth.
Employees in the company, segment and market as a whole
Number of employees in the company Exelixis Inc.
Exelixis is a biotechnology company focused on the development and commercialization of cancer treatments. Its team consists primarily of scientists and clinical research specialists. The growth illustrated by this graph is directly related to progress in the development of new drugs and the expansion of research on existing products.
Share of the company's employees Exelixis Inc. within the market segment - Oncology targeted therapy
Exelixis is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of difficult-to-treat cancers. This indicator reflects its scientific strength. It demonstrates the significant number of scientists and oncologists working on the development of targeted cancer therapies that Exelixis brings together, advancing innovative treatment methods.
Number of employees in the market segment - Oncology targeted therapy
Exelixis is a biotechnology company focused on developing drugs to treat oncology. This chart reflects employment growth in the science-intensive biopharma sector. The number of scientists and researchers in this sector is growing thanks to breakthroughs in understanding cancer biology and the need to develop new targeted therapies.
Number of employees in the market as a whole
Exelixis is a biotechnology company focused on developing cancer treatments. Its success depends on research and drug commercialization. The overall economic situation, reflected in the employment graph, impacts the healthcare system. Stable employment means more insured patients who can access innovative treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Exelixis Inc. (EXEL)
Exelixis is a biotech company that achieved success with its kidney cancer treatment. This chart shows how a scientific breakthrough creates colossal value. The high market capitalization per employee indicates that a small team of scientists and managers was able to create and commercialize a blockbuster drug that generates enormous revenue.
%20of%20the%20company%20Exelixis%20Inc.%20(EXEL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Exelixis-Inc.-EXEL&v=1772513605195 "Chart of market capitalization per employee (in thousands of dollars) of the company Exelixis Inc. (EXEL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Exelixis is a biotech company focused on cancer drug discovery and development, best known for its drug Cabometyx. It is an R&D-focused business. This chart shows the average market capitalization per employee in the sector. It helps understand how the market values Exelixis's scientific potential and commercial success per scientist and employee compared to other biotech companies.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772513605199 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Exelixis is a biopharmaceutical company focused on developing cancer drugs. In biotech, intellectual property—drug patents and clinical trial results—is the primary value. This graph demonstrates the high market valuation per employee, as a small team of scientists can create a blockbuster with multibillion-dollar sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513605203 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Exelixis Inc. (EXEL)
Exelixis is a biotech company focused on cancer drug development, best known for its drug Cabometyx. Profits are generated by intellectual property (patents), not mass production. This chart illustrates how productive R&D is. It reflects how a relatively small team of scientists and managers can generate enormous profits per employee thanks to the success of a single blockbuster.
%20Chart%20Exelixis%20Inc.%20(EXEL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Exelixis-Inc.-EXEL&v=1772513605212 "Company Profit Per Employee (in thousands of dollars) Chart Exelixis Inc. (EXEL)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Exelixis is a biotech company (focused on oncology, with the blockbuster Cabometyx). This chart shows the benchmark for "oncology." The average profit per employee in this sector is astronomical. It's a "blockbuster business." A single successful drug patent can generate billions, more than covering R&D costs and ensuring high profits per scientist.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772513605226 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Exelixis is a biotech company focused on developing cancer drugs. The company's core value is created in laboratories by a small team of scientists and researchers. This graph illustrates the classic model of a science-intensive business: a successful drug can generate billions in revenue, providing a colossal profit per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513605228 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Exelixis Inc. (EXEL)
Exelixis is a biotech company focused on cancer treatment. This chart shows the commercial success of its drugs. High revenue per employee reflects the high value and demand for patented drugs. This metric measures scientific and commercial efficiency—the ability to convert innovation into revenue—rather than production efficiency.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Exelixis-Inc.-EXEL&v=1772513605233 "Sales chart per company employee Exelixis Inc. (EXEL)")
Sales per employee in the market segment - Oncology targeted therapy
Exelixis is a biotech company focused on developing cancer drugs, specifically its blockbuster drug, Cabometyx. For a biotech company, this metric can be very high if a single successful drug generates billions in revenue. The graph shows how effectively their team (primarily R&D and sales) monetizes their research.
Sales per employee for the market as a whole
Exelixis is a biotech company focused on developing and commercializing oncology drugs, best known for its drug Cabometyx. This chart shows how much revenue each employee generates. The high numbers reflect the fact that a single successful, patented drug can generate billions in revenue without requiring a huge production or sales staff.
Short shares by company, segment and market as a whole
Shares shorted by company Exelixis Inc. (EXEL)
Exelixis is a biotech company focused on cancer treatment. Its primary revenue source is Cabometyx. This reliance on a single product is both its strength and its weakness. This chart shows how many investors are betting on a decline. Bears may expect increased competition for Cabometyx or failures in clinical trials of new drugs that would drive future growth.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Exelixis-Inc.-EXEL&v=1772513605264 "Short Shares Chart for the Company Exelixis Inc. (EXEL)")
Shares shorted by market segment - Oncology targeted therapy
Exelixis specializes in developing innovative cancer drugs. Success in biotech depends not only on science but also on regulations and pricing. This indicator reflects the overall volume of short positions in the biotech sector. An increase in short positions in the industry often indicates that investors fear stricter FDA policies or political pressure on drug prices.
Shares shorted by the overall market
Exelixis (EXEL) is a biopharmaceutical company focused on cancer treatment, known for its blockbuster drug, Cabometyx. This chart shows the overall level of market fear. When pessimism increases, investors seek "defensive" sectors. Demand for EXEL's life-saving oncology drugs is recession-resistant, making the company an "island of stability."
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Exelixis Inc. (EXEL)
Exelixis is a biotech company whose success is largely based on the blockbuster Cabometyx. **This chart** measures reactions to binary events. News that Cabometyx has failed a trial for a new type of cancer could trigger panic (below 30). Conversely, a successful trial would trigger euphoria (above 70).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Exelixis-Inc.-EXEL&v=1772513605311 "RSI 14 indicator chart for the company's stock Exelixis Inc. (EXEL)")
RSI 14 Market Segment - Oncology targeted therapy
Exelixis (EXEL) is a biotech whose fate depends almost entirely on a single oncology drug, Cabometyx. It's a risky but rewarding bet. This chart shows the overall sentiment in the biotech sector. It helps us understand: is EXEL oversold due to fears of competition for Cabometyx, or is there a general cooling toward the entire sector?
RSI 14 for the overall market
Exelixis (EXEL) is a biotech company focused on cancer drug development, best known for its drug Cabometyx. Their success depends on clinical trials. This graph of overall risk appetite is important for biotech companies. During periods of euphoria, investors are willing to take risks by investing in research. During times of panic, they flee the volatile sector, fearing trial failures.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EXEL (Exelixis Inc.)
Exelixis is a biotech company focused on oncology. Their flagship drug, Cabometyx, is used to treat several types of cancer, primarily kidney cancer. This chart shows the average 12-month target from analysts. It reflects their forecasts for Cabometyx sales and the success of clinical trials of new combinations.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EXEL-Exelixis-Inc.&v=1772513605376 "A chart showing analyst consensus forecasts for the expected stock price. EXEL (Exelixis Inc.)")
The difference between the consensus estimate and the actual stock price EXEL (Exelixis Inc.)
Exelixis is a biotech company focused on oncology. Their success rests almost entirely on a single blockbuster drug, Cabometyx (for kidney and liver cancer). This chart shows how analysts view their efforts to expand the use of this drug and find new candidates. It reflects the gap between the consensus estimate and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EXEL-Exelixis-Inc.&v=1772513605426 "A chart showing the difference between the consensus forecast and the actual stock price. EXEL (Exelixis Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Exelixis is a biotech company focused on oncology. Its main revenue is generated by the blockbuster Cabometyx (a kidney cancer treatment). This chart shows analysts' overall expectations for the entire targeted oncology sector. It reflects whether experts believe in the success of the company's R&D pipeline or are wary of relying on a single hit.
Analysts' consensus forecast for the overall market share price
Exelixis is a biotech company focused on oncology (their flagship is Cabometyx). Their success is driven by science and sales of existing drugs. Market expectations, visible in this chart, influence the entire biotech sector, determining risk appetite. But for Exelixis, which has a profitable product, this background is less important than for R&D startups.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Exelixis Inc.
Exelixis is a biotech company focused on oncology. Their financial health depends almost entirely on the success of their flagship drug, Cabometyx, used to treat kidney and liver cancer. This chart is essentially a valuation of this single product. It reflects current Cabometyx sales and market confidence in their ability to expand its use.
AKIMA Market Segment Index - Oncology targeted therapy
Exelixis is a biotech focused on oncology; its key asset is the blockbuster Cabometyx, a standard treatment for kidney cancer. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: to what extent does Exelixis's dominance in kidney cancer (and its R&D pipeline) differentiate it from the average pharma company?
The AKIM Index for the overall market
Exelixis is a biotech company focused on oncology. Its success is built on the blockbuster Cabometyx (a kidney cancer treatment). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to general economic trends that influence risk appetite.
